8-K: Milestone Scientific Completes $2.15M Private Placement

Milestone Scientific Inc. has closed a $2.15 million private placement of units, consisting of common stock and warrants, to strengthen its balance sheet and fund commercial growth.

Summary

• Milestone Scientific Inc. announced the closing of a $2.15 million private placement financing on April 20, 2026.
• The financing involved the sale of 7,962,963 units at $0.27 per unit.
• Each unit comprises one share of common stock and one warrant to purchase an additional share.
• The warrants have an exercise price of $0.3375 per share and are exercisable for three years.
• Gross proceeds were $2.15 million, including $1.80 million in cash and $351,000 from the conversion of convertible bridge notes.
• An additional $2.69 million could be raised if all warrants are exercised.
• The company intends to use the net proceeds for general working capital and to pay past-due accounts payable.
• Certain directors and officers participated in the placement, investing $150,000 in cash and converting $351,000 in bridge notes.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the financing strengthens the balance sheet and provides capital for growth, but the need to pay past-due accounts and the dilutive nature of warrants temper the overall sentiment.

Positives

• Successfully closed a private placement raising $2.15 million, strengthening the company's financial position.
• Secured additional potential capital of up to $2.69 million through the exercise of warrants.
• Participation from directors and officers, including the CEO and Chairman, signals confidence in the company's direction.
• No placement agent was used, meaning no placement or underwriting fees were paid, maximizing proceeds.
• The financing supports the company's commercial growth strategy, including investments in sales, inventory, and digital marketing.
• The company is focused on cost discipline despite scaling investments.

Negatives

• The company is using proceeds to pay past-due accounts payable, indicating prior financial strain.
• The exercise price of warrants is 125% of the unit purchase price, diluting existing shareholders upon exercise.
• The financing was conducted via a private placement, which may be perceived as a sign of difficulty accessing public markets.
• The company's stock is trading at a low price ($0.27 per unit), reflecting market valuation concerns.

Risks

• The company's ability to achieve expected revenue growth and manage operating expenses.
• Adverse patent rulings, FDA or legal developments.
• Competitive pressures in the market.
• Changes in customer and market requirements and standards.
• The risk factors detailed in the company's periodic filings with the SEC, including its Annual Report for the year ended December 31, 2025.
• Potential dilution from the exercise of warrants.
• The company's reliance on future warrant exercises for additional capital.

Future Outlook

The company expects to use the net proceeds for general working capital purposes and payment of past due accounts payable. The financing is intended to strengthen the balance sheet and position the company to capitalize on increasing demand, scaling investment in sales, inventory, and digital marketing.

Management Comments

• "Today we strengthened our balance sheet and positioned the company to capitalize on the increasing demand we are seeing across our product platforms," said Eric Hines, Chief Executive Officer of Milestone Scientific.
• "This financing allows us to build on our progress, scaling investment in sales, inventory and digital marketing, while maintaining our continued focus on cost discipline."
• "Importantly, participation from long-term investors and members of the Board, myself included, represents a strong endorsement of our technology and the direction of this Company."

Industry Context

StockSavvy.ai notes that this private placement financing is a common strategy for companies in the medical technology sector to secure capital for growth and operational needs, especially when facing working capital challenges or past-due accounts payable. The participation of insiders and long-term investors is often viewed positively, signaling confidence, but the low per-unit price and reliance on warrant exercise for significant additional capital may indicate current market valuation pressures.

Comparison to Industry Standards

• The structure of the financing, involving units of stock and warrants, is a standard practice in the biotech and medical device industries for raising capital, particularly for companies seeking to avoid immediate dilution from a straight stock offering.
• The use of proceeds for working capital and past-due accounts payable is typical for companies in transitional phases or those experiencing cash flow constraints.
• The conversion of convertible bridge notes by directors and officers at a modified floor price reflects a common mechanism to resolve outstanding debt while aligning insider interests with new equity investors, though the amendment of the conversion floor from $0.50 to $0.27 is a notable concession.
• The reliance on a private placement rather than a public offering suggests the company may be prioritizing speed and avoiding the extensive disclosure and regulatory hurdles of a public offering, or that market conditions for a public offering were less favorable at the time.

Corporate Governance

Related Party Transactions

• Certain directors and officers participated in the private placement, purchasing $150,000 of units for cash.
• Certain directors and officers converted $351,000 in principal and interest from Convertible Bridge Notes into units in the private placement.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares and warrants. Insider participation may be viewed positively as a sign of confidence.
• Creditors: The use of proceeds to pay past-due accounts payable will benefit existing creditors.
• Employees: Improved financial stability may support continued operations and growth initiatives.
• Management: Participation in the financing aligns management's interests with those of new investors.

Next Steps

• Use net proceeds for general working capital purposes.
• Pay past-due accounts payable.
• Scale investment in sales, inventory, and digital marketing.
• File a registration statement with the SEC on or prior to the 45th calendar day after the closing under the Purchase Agreement to register resale of shares.
• Keep the registration statement effective for the duration specified in the Registration Rights Agreement.

Key Dates

Recommendation

The financing provides necessary capital for operations and growth, and insider participation is a positive signal. However, the need to pay past-due accounts, the dilutive nature of warrants, and the low per-unit price suggest that the company still faces significant challenges. A 'hold' recommendation reflects a balanced view of the immediate capital infusion against ongoing operational and market risks.

Keywords

Milestone Scientific, Private Placement, Securities Purchase Agreement, Warrants, Common Stock, Financing, Working Capital, Convertible Bridge Notes